Donanemab for Alzheimer's in Down syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests if an investigational drug called donanemab can lower amyloid plaques in the brain to slow Alzheimer's disease in adults with Down syndrome. Participants must be 35–50, have elevated brain amyloid, and not have dementia yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 35 to 50 years old.
- You have Down syndrome confirmed by a genetic test or medical records.
- You do not have dementia and are in generally good health.
- You have higher-than-normal levels of a brain protein called amyloid (measured by a PET scan or blood test).
- You have a study partner (like a family member or caregiver) who can join visits and report on your health.
- You are not pregnant or planning pregnancy, and agree to avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study tests whether a supplement that boosts a natural substance called NAD (which helps cells work properly) can slow or stop memory loss in people with Down syndrome. You and your caregiver would visit a clinic for regular checkups and take the supplement daily.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
This study looks at how well a brain chemical system works in adults with Down syndrome as they age, including how it relates to Alzheimer’s-type brain changes and thinking skills. It uses brain scans and memory/thinking tests to see whether these measures can help track risk or changes over time.
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
Hear when a new Down Syndrome (Trisomy 21) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.